micobiomed 产品代理
micobiomed 产品代理
我们已经克服了传统IVD设备的无数限制，开发了一种基于“芯片实验室”（Lab-on-a-Chip）的突破性技术，使我们能够快速准确地提供POCT（护理点测试）。
自2020 2019冠状病毒疾病爆发以来，我们自豪地说，我们的深度生物技术、奉献精神和技术已经在全球对抗全球流行的前沿。
在我们积极应对最紧迫的全球健康威胁的同时，我们也抓住了许多机会，实现了前所未有的增长，并成功完成了我们在KOSDAQ的IPO。
最近，2019冠状病毒疾病2019冠状病毒疾病的全球疫苗接种工作和新的COVID-19变种的连续出现密切相关。现在，我们正在为后新冠肺炎时代做准备，我们正在成为全球POCT市场的游戏规则改变者。
Molecular Diagnostics
Biochemical Diagnostics
Immunodiagnostics
Ever since our establishment in 2009, We, MiCo BioMed has been committed to improving and saving lives by offering innovative, market-leading IVD technologies.
We have been overcoming countless limitations of traditional IVD devices by developing a groundbreaking “Lab-on-a-Chip” (LabChip)-based technology which enable us to deliver POCT (Point-of-care Testing) quickly and accurately.
Since the outbreak of COVID-19 pandemic in 2020, we are proud to say that MiCo BioMed, with our deep expertise, dedication, and technologies, has been at the forefront of the global fight against the pandemic.
As we have been actively tackling the most pressing global health threat, we also have seized many opportunities to show unprecedented growth and successfully completed our IPO on KOSDAQ.
Recently we are closely keeping track of the global COVID-19 vaccination effort and continuous emergences of new COVID-19 variants. Now preparing ourselves for a post-COVID-19 era, we are evolving to be a game-changer in the global POCT market.
